StockData
Envista Holdings Corp logo

Envista Holdings Corp (NVST) company profile

NVSTNYSEDental Equipment & SuppliesFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jul 3, 2026Last filing: 10-Q on Nov 4, 2026Score 14/3017% below fair value
$24.03−0.46 (-1.88%)

Close on Nov 16, 2026Market cap $3.86BP/E 41.4Yield –

About Envista

Dental Equipment & Supplies, SIC 3843

Envista develops, manufactures, and markets dental products, equipment, and software solutions worldwide. The company operates through two segments: Specialty Products & Technologies, and Equipment & Consumables. Its portfolio includes dental implant systems, regenerative solutions, prosthetics, orthodontic brackets and wires, clear aligners, digital imaging systems, endodontic and restorative materials, rotary burs, and infection prevention products. Envista serves dental specialists—including orthodontists, periodontists, implantologists, endodontists, and oral surgeons—as well as general dentists, dental hygienists, dental laboratories, dental service organizations, and distributors.

The company employs approximately 12,000 individuals, with roughly 3,000 in the United States and 9,000 internationally. Envista serves dental professionals across more than 130 countries, conducting business in North America, Western Europe, and various emerging and developed markets. It conducts research and development activities primarily in North America, the Middle East, and Europe. The provided text mentions no headquarters location.

Summary of the business section of Envista's latest annual report, written by StockData.

Company profile

Company

Legal name
Envista Holdings Corp
Founded
2018
Headquarters
Brea, CA
Address
200 S. Kraemer Blvd., Bldg. E 92821
Phone
(714) 817-5418
Employees
12,000, Dec 31, 2025
Industry
Dental Equipment & Supplies
Incorporated in
Delaware
Fiscal year ends
December 31
Auditor
Ernst & Young LLP, Irvine, California

Stock & identifiers

Ticker
NVST
Exchange
NYSE
IPO date
Sep 19, 2019
Shares outstanding
161M, Jul 31, 2026
Public float
$2.50B, Jun 27, 2025
Filer category
Large accelerated filer
SEC CIK
1757073
CUSIP
29415F104
ISIN
US29415F1049
FIGI
BBG00LN4B5N0
Share class FIGI
BBG00LN4B6D9
LEI
549300BX623VURJZ5269
EIN
83-2206728

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
Paul A. KeelChairman and CEO, Director497,107
Robert BefidiPresident, Diagnostics45,785
Veronica AcurioPresident, Orthodontics48,806
Eric D. HammesChief Financial Officer99,913
Stefan NilssonPresident, Nobel Biocare61,560
Mischa ReisSVP, Strategy & Bus. Dev.27,321
Coree K. ThomasCAO2,535
Faez C. KaabiChief Accounting Officer58,552
Mark E. NanceGeneral Counsel68,577
Daniel RaskasDirector54,010
Christine A. TsingosDirector59,930
Vivek JainDirector52,945
Wendy CarruthersDirector59,940
R. Scott HuennekensDirector82,105
Kieran GallahueDirector54,010
James Andrew PierceDirector18,485
Barbara B. HulitDirector79,820

CEO pay and shareholder return

Pay versus performance table from the proxy statement

Fiscal yearCEO total payCEO pay actually paidOther executives (avg)Value of $100 investedPeer group
FY2025$10.56M$14.25M$2.35M$64$136
FY2024
Amir Aghdaei
$8.92M$4.21M$2.37M$57$121
FY2024
Paul Keel
$23.83M$22.80M$2.37M$57$121
FY2023$7.06M-$1.82M$1.68M$71$120
FY2022$8.52M-$4.54M$1.84M$100$120
FY2021$9.20M$28.84M$2.47M$134$124

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

Executive compensation, fiscal 2025

Summary compensation table from the latest proxy statement

ExecutiveSalaryStock awardsOption awardsIncentive payOtherTotalvs. prior year
Paul Keel
President & CEO
$1.10M$5.44M$1.36M$2.49M$172.82K$10.56M-56%
Eric Hammes
Chief Financial Officer
$592.31K$975.15K$325.01K$739.80K$13.70K$2.65M-7%
Mark Nance
SVP and General Counsel
$559.62K$1.13M$375.02K$551.43K$33.99K$2.65M-15%
Veronica Acurio
President, Orthodontics
$550.00K$637.67K$212.51K$720.72K$52.20K$2.17M–
Robert Befidi
President, Diagnostics
$567.31K$637.67K$212.51K$470.93K$47.85K$1.94M-16%

Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.

IPO

From the final prospectus (Form 424B4) and the first day of trading

Offering

Type
Initial public offering
Final prospectus filed
Sep 19, 2019
Offer price
$22.00
Securities offered
26,768,000
Gross proceeds
$588.90M
Exchange
NYSE
Lock-up ends (est.)
Mar 17, 2020

“The initial public offering price is $22.00 per share of common stock.”

Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.

Employees

Headcount reported in annual reports

“As of December 31, 2025, we employed approximately 12,000 persons, of whom approximately 3,000 were employed in the U.S.”

Corporate history

Events identified from SEC filings

See a number that looks wrong?